Skip to Main Content
May 17, 2017 at 9:20 AM
Falsely lower test results may lead to improper patient management and treatment for lead exposure or poisoning.
May 16, 2017 at 11:00 AM
Potential risks associated with balloon inflation and deflation difficulties include air embolism, additional intervention, thrombosis, and myocardial infarction.
May 16, 2017 at 9:00 AM
New warnings, including a Boxed Warning, to be added to the canagliflozin drug labels.
May 08, 2017 at 3:30 PM
UPDATED 5/8/2017. C.O. Truxton expands their 04/21/2017 recall to include additional products.
May 08, 2017 at 8:15 AM
Use or consumption of products containing anabolic steroids may cause acute liver injury. Abuse of anabolic steroids may cause other serious long-term adverse health consequences in men, women, and children.
May 08, 2017 at 12:00 AM
UPDATED 5/8/2017. C.O. Truxton, Inc. Issues Voluntary Nationwide Recall of Amitriptyline HCL Tablets, USP 50mg and Phenobarbital Tablets, USP 15mg, 30mg, 60mg, 100mg Due to Potential Label Mix-Up.
May 05, 2017 at 2:10 PM
An interruption in electrical connection may cause the pump to stop, which may lead to serious adverse health consequences, including death.
May 04, 2017 at 1:30 PM
Loose connector may allow moisture to enter controller causing corrosion, electrical issues, reduced speaker volume and connection failures which could cause serious adverse health consequences, including death.
May 03, 2017 at 3:00 PM
Tip splitting has the potential to lead to loss of device function. Tip separation may require medical intervention to retrieve a separated segment or may occlude blood flow to end organs.
May 03, 2017 at 9:55 AM
Minor and serious injuries, including two patient deaths, following procedures that involved the use of non-Medtronic instruments with Medtronic's NavLock Tracker.
May 02, 2017 at 3:01 PM
UPDATED 05/02/2017. Class I Recall. Potential for ventilator reset during normal operation, without an accompanying alarm.
April 27, 2017 at 1:15 PM
Exposure to these medicines for lengthy periods of time or over multiple surgeries or procedures may negatively affect brain development in children younger than 3 years.
April 25, 2017 at 9:25 AM
Use of unproven or unapproved products may be unsafe and could prevent a person from seeking an appropriate and potentially life-saving cancer diagnosis or treatment.
April 24, 2017 at 10:05 AM
Particulate administered to a patient could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or systemic allergic response to the particulate.
April 21, 2017 at 2:10 PM
Mislabeled product could expose the consumer or their pet(s) to potential overdosing that can cause severe intoxication which may lead to cardiogenic shock, renal failure, coma or death.
April 20, 2017 at 11:30 AM
New and strengthened WARNINGS and CONTRAINDICATIONS on drug labels describing serious risks, including slowed or difficult breathing and death.
April 19, 2017 at 8:55 AM
Use of these products may pose a threat to consumers because the undeclared ingredients may interact with nitrates found in some prescription drugs and may lower blood pressure to dangerous levels.
April 13, 2017 at 7:00 PM
Updated 04/13/2017. Homeopathic teething products containing belladonna pose an unnecessary risk to infants and children.
April 08, 2017 at 9:29 PM
If left untreated, under-drainage can potentially lead to coma and death.
April 06, 2017 at 4:35 PM
Voluntary recall of all lots of sterile products, to the hospital/user level.
April 05, 2017 at 1:40 PM
Potential for ventilator reset during normal operation, without an accompanying alarm.
March 31, 2017 at 7:00 PM
Failure to activate or increased force needed to activate may have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis).
March 31, 2017 at 1:30 PM
Tip could enter the patient's bloodstream, resulting in prolonged procedure times, additional surgery to remove the tip from the patient, blood clots, internal tears and perforation to arteries or veins, excessive bleeding, and death.
March 30, 2017 at 9:50 AM
Sibutramine may substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
March 24, 2017 at 1:20 PM
A delay in delivering therapy could result in serious patient injury such as permanent organ damage, brain injury, or death.